Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

Core Insights - Myriad Genetics, Inc. announced a study showing that the use of an online screening tool and education significantly increased the completion rate of hereditary cancer testing among patients [1][2][3] Study Findings - The study evaluated the impact of MyGeneHistory®, an online patient screening tool, and a virtual education program on hereditary cancer testing completion rates [2][6] - Approximately 30% more patients were identified as meeting the guidelines for hereditary cancer testing (HCT) after implementing the online tool [8] - There was a 50% increase in the number of patients who met the guidelines and were offered HCT [8] - More than twice the number of patients completed HCT following the implementation of the new tools [8] Clinician Feedback - Clinicians reported increased confidence in administering hereditary cancer risk assessments, with 87% stating that the online screening and education tools helped them adhere to recommended standards of care [3] - Over 80% of providers believed the program assisted them in following ACOG guidelines for hereditary cancer risk assessment [3] Program Overview - Myriad's Breast Cancer Risk Assessment Program includes the MyRisk® with RiskScore® Hereditary Cancer Test and the MyGeneHistory online screening tool [5] - The program aims to improve patient access and education regarding genetic testing [4][5] Study Details - The study involved over 10,000 patients across five U.S. community obstetrics/gynecology practices, with an eight-week observation period followed by training on the online tools [6]